Clinical trials
Gastrointestinal Cancer Metastatic clinical trials
Below are recruiting gastrointestinal cancer metastatic clinical trials, each written for real people, not researchers. We’re tracking 428 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05955170RecruitingPhase 2
Tucatinib plus oral chemo and trastuzumab for metastatic HER2+ breast cancer
This Phase 2 trial studies tucatinib combined with oral etoposide and trastuzumab in people with metastatic HER2-positive breast cancer, aiming to slow cancer growth. You may be eligible if you previously had progression on a similar HER2-targeted treatment or cannot take capecitabine for medical reasons.
Clermont-Ferrand, Clermont FerrandAges 18 years+ - NCT05954429RecruitingPhase 2
Study of fruquintinib plus immunotherapy after standard CRC treatment
This trial studies fruquintinib combined with serplulimab (an immune therapy) for advanced colorectal cancer that has spread and is no longer responding to standard treatments. It may help by slowing the cancer’s growth and improving outcomes after the usual options have been tried.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04878029RecruitingPhase 1
Cabozantinib plus enfortumab for advanced bladder cancer after immunotherapy
This Phase 1 study tests whether cabozantinib combined with enfortumab vedotin can help people with advanced urothelial (bladder) cancer that has already been treated with immunotherapy (PD-1/PD-L1) and usually chemotherapy. It aims to find a safer dose and see if the combo can shrink tumors or control the disease.
Atlanta, GeorgiaAges 18 years+ - NCT04965064RecruitingPhase 2
Neratinib plus capecitabine for HER2-negative breast cancer brain mets
This study tests whether neratinib plus capecitabine can slow or shrink breast cancer that has spread to the brain. It is for people whose cancer shows an “overactive HER2 signal” on a specific tumor test, even though their cancer is labeled HER2-negative.
Rochester, New YorkAges 18 years+ - NCT05800275RecruitingPhase 2
Tucatinib and capecitabine plus spinal trastuzumab for HER2+ cancer
This Phase 2 trial tests a combination of tucatinib and capecitabine (taken by mouth) plus trastuzumab delivered into the spinal fluid, to treat breast cancer that has spread to the leptomeninges (lining around the brain/spinal cord). It may help reduce cancer activity in the spinal fluid and improve symptoms.
BordeauxAges 18 years+ - NCT07336446RecruitingPhase 1/Phase 2
Testing AZD9750 for metastatic prostate cancer with or without other drugs
This trial is for men with metastatic prostate cancer that has gotten worse despite treatment. It tests a new drug called AZD9750, given alone or with other cancer drugs, to see if it is safe and works well.
Duarte, CaliforniaAges 18 years+ - NCT04090567RecruitingPhase 2
Olaparib with two partners for advanced BRCA breast cancer
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
Houston, TexasAges 18 years+ - NCT06461156RecruitingPhase 1
New targeted drug study for EGFR-mutated lung cancer
This trial tests a new targeted drug (HS-10504) for people with advanced EGFR-mutated non-small cell lung cancer that has worsened after previous EGFR inhibitor therapy. The study aims to see if this drug can help shrink tumors or slow cancer growth.
GuangzhouAges 18 years+ - NCT07175220RecruitingPhase 2
Study of SHR2554 tablets combined with other treatments for lung cancer
This trial tests a new drug combination for people with non-small cell lung cancer that has spread or cannot be removed by surgery. It aims to see if adding SHR2554 tablets to other anticancer treatments can help control the disease.
Guangzhou, GuangdongAges 18–75 - NCT05970302RecruitingPhase 2
XELOX, bevacizumab, and immunotherapy for metastatic colon cancer
This Phase 2 trial studies a combination treatment (XELOX plus bevacizumab plus an immunotherapy drug) for people with metastatic colon cancer that has certain lab features (MSS/pMMR and RAS-mutated). It aims to see how well the treatment works as a first treatment when the cancer cannot be removed with surgery.
BeijingAges 18 years+ - NCT06640166RecruitingPhase 2
Encorafenib + Cetuximab with FOLFIRI after progression
This trial tests adding a new chemotherapy regimen (FOLFIRI) to the combination of Encorafenib and Cetuximab for people with a specific type of advanced colorectal cancer that has started growing again after initial treatment with Encorafenib and Cetuximab. The goal is to see if the new combination can help control the cancer longer.
MilanAges 18 years+ - NCT06689163RecruitingPhase 1/Phase 2
Study of HRS-1167 with abiraterone for metastatic prostate cancer
This trial tests a new combination of two study drugs (HRS-1167 and abiraterone with prednisone) for men with prostate cancer that has spread beyond the prostate. The goal is to see if the combination works better than current treatments.
Hefei, AnhuiAges 18 years+ - NCT07446452RecruitingPhase 2
Combination treatment for HER2-low advanced breast cancer
This trial tests a combination of two drugs, disitamab vedotin and bevacizumab, for people with a specific type of advanced breast cancer called HER2-low. It is designed for those who have already been treated with a drug called T-DXd and need further options.
Nanjing, JiangsuAges 18–75 - NCT06549907Recruiting
Study of double immunotherapy plus anti-angiogenic therapy
This trial studies people with certain types of colorectal or other solid tumors that did not respond to a single immunotherapy drug. It tests whether adding a second immune checkpoint blocker and an anti-angiogenic drug can help control the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06086457RecruitingPhase 3
Immunotherapy plus chemo with or without radiation for esophageal cancer
This trial tests whether adding radiation therapy to a standard treatment (immunotherapy plus chemotherapy) can help people with advanced esophageal cancer that has spread to up to two organs. The goal is to see if the combination improves outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06016387RecruitingPhase 2
Drug combo with radiation for HER2+ breast cancer spread to spinal lining
This trial tests a combination of three targeted drugs (tucatinib, trastuzumab, and capecitabine) along with radiation to the brain or spine for people whose HER2-positive breast cancer has spread to the lining of the brain or spinal cord. The goal is to see if this treatment is safe and effective.
Ottawa, OntarioAges 18 years+ - NCT06079346RecruitingPhase 2/Phase 3
New drug with chemotherapy for advanced pancreatic cancer
This trial tests a new drug called OT-101 combined with a standard chemotherapy regimen (mFOLFIRINOX) for people with advanced pancreatic cancer that has spread or cannot be removed. The goal is to see if the combination can help shrink or control the cancer better than chemotherapy alone.
Detroit, MichiganAges 18 years+ - NCT07686835RecruitingPhase 2
High-fiber diet to help immunotherapy work better in advanced melanoma
This trial tests if adding extra dietary fiber before and during immunotherapy can change gut bacteria to make the treatment more effective. It is for people with advanced melanoma who are about to start their first immunotherapy.
Nijmegen, GelderlandAges 18 years+ - NCT05253651RecruitingPhase 3
Tucatinib plus trastuzumab with chemo for HER2+ metastatic colon cancer
This trial tests whether adding tucatinib and trastuzumab to standard chemotherapy works better than standard treatment alone for people with HER2-positive metastatic colon or rectal cancer. It aims to improve how long people live and how well tumors respond as first treatment for advanced disease.
Glendale, ArizonaAges 18 years+ - NCT05229003RecruitingPhase 2
Irinotecan, anlotinib, and pembrolizumab-like drug for advanced colon cancer
This Phase 2 study tests adding anlotinib and penpulimab to irinotecan for colorectal cancer that has come back or spread after earlier chemotherapy. It may help shrink tumors and control the disease when standard first-line treatment no longer works.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT05277935Recruiting
Wearable activity tracking for hormone-positive metastatic breast cancer
This study tests whether using a wearable watch and smartphone app to track activity and fitness can help monitor health in people with hormone receptor–positive, HER2-negative metastatic breast cancer while they take standard hormone therapy plus palbociclib. It mainly requires that you are already on these medicines for at least three months and can use the devices reliably.
Rio de JaneiroAges 18 years+ - NCT05970705RecruitingPhase 2
Regorafenib plus TAS-102 versus regorafenib alone for advanced bowel cancer
This Phase 2 study tests whether adding TAS-102 to regorafenib works better than regorafenib by itself for metastatic colorectal cancer after at least one prior treatment has stopped working. It aims to improve how long the cancer can be controlled for patients in later treatment lines.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06439771RecruitingPhase 2
Testing YL202 for advanced breast cancer
This trial tests a new drug called YL202 for people with advanced breast cancer. It is for those who have already tried certain targeted treatments (HER2 or TROP2 antibody-drug conjugates) and they stopped working. The goal is to see if YL202 can help shrink tumors or slow cancer growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06485713RecruitingPhase 2
Third-line therapy for advanced colorectal cancer
This trial tests a combination of two oral cancer drugs, trifluridine/tipiracil and fufuquitinib, as a third-line treatment for people with advanced colorectal cancer. It may be an option if prior treatments have stopped working.
Wenzhou, ZhejiangAges 18–75
Hear when a new Gastrointestinal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastrointestinal cancer metastatic?
- Yes. Clin2 currently lists 428 recruiting gastrointestinal cancer metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastrointestinal cancer metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastrointestinal cancer metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.